Zyvox® (linezolid), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections

被引：0

作者：

Brickner, Steven J. ^{[1
]}

Barbachyn, Michael R. ^{[2
]}

Hutchinson, Douglas K. ^{[3
]}

Manninen, Peter R. ^{[4
]}

机构：

[1] Pfizer Inc, Antibacterials Chem, Groton New London Labs, Groton, CT 06340 USA

[2] Pfizer Inc, Dept Chem, Ann Arbor, MI 48105 USA

[3] Abbott Labs, Abbott Pk, IL 60064 USA

[4] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2007年 / 233卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

257-MEDI

引用

页码：607 / 607

页数：1

共 50 条

[21] Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review
Françoise Van Bambeke
Drugs, 2015, 75 : 2073 - 2095
[22] Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review
Van Bambeke, Francoise
DRUGS, 2015, 75 (18) : 2073 - 2095
[23] Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children
Kaplan, SL
Deville, JG
Yogev, R
Morfin, MR
Wu, E
Adler, S
Edge-Padbury, B
Naberhuis-Stehouwer, S
Bruss, JB
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (08) : 677 - 685
[24] Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections
Wilcox, M
Nathwani, D
Dryden, M
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (02) : 335 - 344
[25] Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections
Steenbergen, JN
Alder, J
Thorne, GM
Tally, FP
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (03) : 283 - 288
[26] Novel agents for the treatment of resistant Gram-positive infections
Woodford, N
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (02) : 117 - 137
[27] Linezolid - A synthetic oxazolidinone antimicrobial for treatment of serious gram-positive infections (vol 35, pg 483, 2000)
CupoAbbott, J
FORMULARY, 2000, 35 (09) : 736 - 736
[28] New treatment option for Gram-positive infections in critically Ill patients overview over linezolid
Krueger, WA
Unertl, KE
ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE, 2002, 37 (04): : 199 - 204
[29] Dalbavancin: A new option for the treatment of gram-positive infections
Lin, SW
Carver, PL
DePestel, DD
ANNALS OF PHARMACOTHERAPY, 2006, 40 (03) : 449 - 460
[30] Dalbavancin: A new milestone in the treatment of Gram-positive infections
Gonzalez, Aristides de Alarcon
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2025, 43 (02): : 61 - 63

← 1 2 3 4 5 →